|Appears in Collections:||Faculty of Health Sciences and Sport Journal Articles|
|Peer Review Status:||Refereed|
|Title:||Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus|
Doney, Alex S F
Al, Zadjali Matlooba
Ogston, Simon A
Petrie, John R
Morris, Andrew D
Struthers, Allan D
Wong, Aaron K F
Lang, Chim C
|Citation:||Evans J, Doney ASF, Al Zadjali M, Ogston SA, Petrie JR, Morris AD, Struthers AD, Wong AKF & Lang CC (2010) Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus, American Journal of Cardiology, 106 (7), pp. 1006-1010.|
|Abstract:||Type 2 diabetes mellitus (DM) plus chronic heart failure (CHF) is a common but lethal combination and therapeutic options are limited. Metformin is perceived as being relatively contraindicated in this context, although mounting evidence indicates that it may be beneficial. This study was carried out to investigate the use of metformin therapy for treating patients with DM and CHF in a large population-based cohort study. The Health Informatics Centre- dispensed prescribing database for the population of Tayside, Scotland (population 400,000) was linked to the Diabetes Audit and Research in Tayside Scotland (DARTS) information system. Patients with DM and incident CHF from 1994 to 2003 receiving oral hypoglycemic agents but not insulin were identified. Cox regression was used to assess differences in all-cause mortality rates between patients prescribed metformin and patients prescribed sulfonylureas with adjustment for co-morbidities and other therapies. Four hundred twenty-two study subjects (mean SD 75.4 0.5 years of age, 46.2% women) were identified: metformin monotherapy (n 68, mean age 75.5 1.1 years, 48.5% women), sulfonylurea monotherapy (n 217, mean age 76.7 0.7 years, 45.2% women), and combination (n 137, mean age, 73.4 0.7 years, 46.7% women). Fewer deaths occurred in metformin users, alone or in combination with sulfonylureas, compared to the sulfonylurea monotherapy cohort at 1 year (0.59, 95% confidence interval 0.36 to 0.96) and over long-term follow up (0.67, 95% confidence interval 0.51 to 0.88). In conclusion, this large observational data suggest that metformin may be beneficial in patients with CHF and DM. These findings need to be verified by a prospective clinical trial.|
|Rights:||The publisher does not allow this work to be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study.|
|Evans_2010_Effect_of_Metformin.pdf||225.42 kB||Adobe PDF||Under Embargo until 31/12/2999 Request a copy|
Note: If any of the files in this item are currently embargoed, you can request a copy directly from the author by clicking the padlock icon above. However, this facility is dependant on the depositor still being contactable at their original email address.
This item is protected by original copyright
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
If you believe that any material held in STORRE infringes copyright, please contact firstname.lastname@example.org providing details and we will remove the Work from public display in STORRE and investigate your claim.